MedTrace Logo

A Study of PLB-002 in Advanced Solid Tumors

NCT07304128 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-03

No results posted yet for this study

Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

PLB-002

antibody drug conjugate (ADC)

Sponsors & Collaborators

  • Primelink BioTherapeitics(ShenZhen) Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-06
Primary Completion
2027-06-30
Completion
2027-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07304128 on ClinicalTrials.gov